Sugi Predict

Sugi Predict / Compounds / SCHEMBL386609

SCHEMBL386609

SCHEMBL386609

C#CCCOc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA3 P22001 1/20 0.58
▸ TAAR1 Q96RJ0 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ HTR1B P28222 2/20 0.47
▸ DRD4 P21917 2/20 0.47
▸ HDAC3 O15379 1/20 0.47
▸ HDAC4 P56524 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC7 Q8WUI4 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47
▸ HDAC10 Q969S8 1/20 0.47
▸ HDAC11 Q96DB2 1/20 0.47
▸ HDAC8 Q9BY41 1/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47
▸ HDAC9 Q9UKV0 1/20 0.47
▸ HDAC5 Q9UQL6 1/20 0.47
▸ DRD2 P14416 1/20 0.47
▸ DRD3 P35462 1/20 0.47
▸ HTR1D P28221 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5382026 0.92 LTA4H (0.58) KCNA3TAAR1ALDH1A1RECQLHDAC1
SCHEMBL9442251 0.89 KCNA3 (0.62) KCNA3TAAR1ALDH1A1RECQLHTR1B
SCHEMBL31725993 0.88 GAA (0.42) KCNA3
SCHEMBL5377741 0.88 LSS (0.51) KCNA3ALDH1A1RECQLHDAC3HDAC4
SCHEMBL11394397 0.87 KCNA3 (0.67) KCNA3TAAR1ALDH1A1RECQLHTR1B
SCHEMBL7214530 0.85 KCNA3 (0.64) KCNA3TAAR1ALDH1A1RECQLHTR1B
SCHEMBL17934729 0.83 KCNA3 (0.41) KCNA3TAAR1ALDH1A1RECQLLTA4H
SCHEMBL159814 0.82 LTA4H (0.61) KCNA3HDAC1HDAC2LTA4HPLA2G2A
SCHEMBL5385295 0.80 GAA (0.66) ALDH1A1LTA4HPKM
SCHEMBL919633 0.80 GAA (0.38) KCNA3TAAR1ALDH1A1RECQLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
CN-119562945-A IKK inhibitors 癌症研究技术有限公司 2025-03-04 — — CN disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed
CN-116354995-A Boron-containing chiral allyl ester compound and high-stereoselectivity synthesis method 武汉大学 2023-06-30 — — CN disclosed
CN-113423427-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2021-09-21 — — CN disclosed
EP-1740579-B1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBVIE INC (US) 2015-08-19 — — EP disclosed
US-8101650-B2 Method for treating a immunology-related disease DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-24 — — US disclosed
US-8067396-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2011-11-29 — — US disclosed
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2010-02-11 — — US disclosed
US-20070105933-A1 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-05-10 — — US disclosed
US-7199150-B2 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-04-03 — — US disclosed
EP-1740579-A1 TRICYCLIC PYRAZOLE KINASE INHIBITORS Abbott Laboratories (US) 2007-01-10 — — EP disclosed
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors ABBVIE INC. 2006-01-19 — — US disclosed
WO-2005095387-A1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-10-13 — — WO disclosed
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO COMPANY, LIMITED (JP) 2005-02-24 — — US disclosed
EP-1471054-A1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE Sankyo Company, Limited (JP) 2004-10-27 — — EP disclosed
WO-1989004595-A2 ECTOPARASITICIDES THE UPJOHN COMPANY (US) 1989-06-01 — — WO disclosed
EP-0076075-B1 PHARMACEUTICALLY ACTIVE BENZOPYRAN COMPOUNDS BEECHAM GROUP PLC (GB) 1986-11-20 — — EP disclosed
US-4446113-A HYPOTENSIVE AGENTS BEECHAM GROUP P.L.C. (GB) 1984-05-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB KCNA3 2650/4885TAAR1 4065/4885ALDH1A1 4083/4885
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these PHOSPHO1, CD4, FCGRT KCNA3 4044/4885TAAR1 218/4885ALDH1A1 945/4885
US-20070105933-A1 Amino alcohol compounds ADH1C, C9, SSB KCNA3 2887/4885TAAR1 28/4885ALDH1A1 582/4885
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors PRKDC, PRKACA, PIK3C3 KCNA3 2872/4885TAAR1 3612/4885ALDH1A1 3901/4885
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof PHOSPHO1, ADH1C, ADH1A KCNA3 3747/4885TAAR1 12/4885ALDH1A1 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.